Cargando…

The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity

AIMS: In the field of radiogenomics, several potential predictive genetic markers have been identified that are associated with individual susceptibility to radiation toxicity. Predictive models of radiation toxicity incorporating radiogenomics and other biomarkers are being developed as part of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rattay, T., Symonds, R.P., Shokuhi, S., Talbot, C.J., Schnur, J.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821695/
https://www.ncbi.nlm.nih.gov/pubmed/29287972
http://dx.doi.org/10.1016/j.clon.2017.12.001
_version_ 1783301537491058688
author Rattay, T.
Symonds, R.P.
Shokuhi, S.
Talbot, C.J.
Schnur, J.B.
author_facet Rattay, T.
Symonds, R.P.
Shokuhi, S.
Talbot, C.J.
Schnur, J.B.
author_sort Rattay, T.
collection PubMed
description AIMS: In the field of radiogenomics, several potential predictive genetic markers have been identified that are associated with individual susceptibility to radiation toxicity. Predictive models of radiation toxicity incorporating radiogenomics and other biomarkers are being developed as part of the ongoing multicentre REQUITE trial. The purpose of this study was to explore patient attitudes towards future predictive radiogenomics testing for breast radiation toxicity. PATIENTS AND METHODS: Twenty-one semi-structured interviews were conducted with breast cancer patients taking part in the REQUITE study at one centre. We used inductive thematic analysis to generate common themes. RESULTS: We identified three emerging themes describing attitudes and feelings towards a predictive radiogenomics test for breast radiation toxicity: theme 1 – willingness to undergo a test (subthemes – information, trusted expert); theme 2 – implications of a test (subthemes – preparation and planning, anxiety without recourse); theme 3 – impact on treatment decision-making (subthemes – prioritising cancer cure, preserving breast integrity, patient preferences). CONCLUSIONS: Results from the present study indicate that patients support and have confidence in the validity of a radiogenomics test for breast radiation toxicity, but they would prefer the result be provided to healthcare professionals. Except in cases of significant chronic symptoms and pain or significant end-organ damage, participants in this study rarely felt that advance knowledge of their personal risk of breast radiation toxicity would influence their treatment decision-making. These findings provide a number of insights that will allow us to anticipate how patients are likely to engage with predictive radiogenomics testing in the future.
format Online
Article
Text
id pubmed-5821695
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-58216952018-03-01 The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity Rattay, T. Symonds, R.P. Shokuhi, S. Talbot, C.J. Schnur, J.B. Clin Oncol (R Coll Radiol) Article AIMS: In the field of radiogenomics, several potential predictive genetic markers have been identified that are associated with individual susceptibility to radiation toxicity. Predictive models of radiation toxicity incorporating radiogenomics and other biomarkers are being developed as part of the ongoing multicentre REQUITE trial. The purpose of this study was to explore patient attitudes towards future predictive radiogenomics testing for breast radiation toxicity. PATIENTS AND METHODS: Twenty-one semi-structured interviews were conducted with breast cancer patients taking part in the REQUITE study at one centre. We used inductive thematic analysis to generate common themes. RESULTS: We identified three emerging themes describing attitudes and feelings towards a predictive radiogenomics test for breast radiation toxicity: theme 1 – willingness to undergo a test (subthemes – information, trusted expert); theme 2 – implications of a test (subthemes – preparation and planning, anxiety without recourse); theme 3 – impact on treatment decision-making (subthemes – prioritising cancer cure, preserving breast integrity, patient preferences). CONCLUSIONS: Results from the present study indicate that patients support and have confidence in the validity of a radiogenomics test for breast radiation toxicity, but they would prefer the result be provided to healthcare professionals. Except in cases of significant chronic symptoms and pain or significant end-organ damage, participants in this study rarely felt that advance knowledge of their personal risk of breast radiation toxicity would influence their treatment decision-making. These findings provide a number of insights that will allow us to anticipate how patients are likely to engage with predictive radiogenomics testing in the future. W.B. Saunders 2018-03 /pmc/articles/PMC5821695/ /pubmed/29287972 http://dx.doi.org/10.1016/j.clon.2017.12.001 Text en © 2017 Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Rattay, T.
Symonds, R.P.
Shokuhi, S.
Talbot, C.J.
Schnur, J.B.
The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity
title The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity
title_full The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity
title_fullStr The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity
title_full_unstemmed The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity
title_short The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity
title_sort patient perspective on radiogenomics testing for breast radiation toxicity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821695/
https://www.ncbi.nlm.nih.gov/pubmed/29287972
http://dx.doi.org/10.1016/j.clon.2017.12.001
work_keys_str_mv AT rattayt thepatientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT symondsrp thepatientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT shokuhis thepatientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT talbotcj thepatientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT schnurjb thepatientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT rattayt patientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT symondsrp patientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT shokuhis patientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT talbotcj patientperspectiveonradiogenomicstestingforbreastradiationtoxicity
AT schnurjb patientperspectiveonradiogenomicstestingforbreastradiationtoxicity